Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib
- 776 Downloads
Data regarding the management and outcome of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to 1st-line imatinib and 2nd-line sunitinib are limited.
Medical records of 223 imatinib-resistant and sunitinib-resistant GIST who were treated in 11 major referral centers were reviewed.
The three most frequent drugs used in the 3rd-line setting were: nilotinib n = 67 (29.5%), sorafenib n = 55 (24.5%), and imatinib n = 40 (17.5%). There were 18 patients (8%) who received best supportive care (BSC) only. The median progression-free survival (PFS) and overall survival (OS) on 3rd-line treatment were 3.6 months [95% confidence interval (95% CI), 3.1–4.1] and 9.2 months (95% CI, 7.5–10.9), respectively. Multivariate analysis showed that, in the 3rd-line setting, albumin level and KIT/PDGFRA mutational status were significantly associated with PFS, whereas performance status and albumin level were associated with OS. After adjustment for prognostic factors, nilotinib and sorafenib provided the best PFS and OS. Rechallenge with imatinib was also associated with improved OS in comparison with BSC.
In the 3rd-line setting, rechallenge with imatinib provided limited clinical benefit but was superior to BSC. Sorafenib and nilotinib have significant clinical activity in imatinib-resistant and sunitinib-resistant GIST and may represent an alternative for rechallenge with imatinib.
KeywordsOverall Survival Imatinib Sorafenib Sunitinib Median Overall Survival
- 1.Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28:1247–53.Google Scholar
- 4.Hamilton SR, Lauri A, editors. Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours. Lyon: IARC; 2000.Google Scholar
- 15.Dileo P, Bauer S, Van Den Abbeele A, Morgan JA, George S, Salesi JM, et al. Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST [abstract]. Presented at ASCO gastrointestinal cancers symposium; January 28–30, 2006; San Francisco, CA; Abstract 53.Google Scholar
- 17.Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, Kanda T, et al. A. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer. 2011. doi: 10.1002/cncr.26120.
- 20.Campbell NP, Wroblewski K, Maki RG, D’Adamo DR, Chow WA, Gandara DR, et al. Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST). J Clin Oncol. 2011;29 Suppl 4; Abstract 4.Google Scholar
- 21.National Comprehensive Cancer Network, NCCN Clinical Practice guidelines in oncology: soft tissue sarcoma. Vol 2. 2010 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
- 22.Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol. 2010;21 Suppl 5:v98–v102.Google Scholar
- 23.Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bin Bui N, et al. Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): first results from ENEST g3. J Clin Oncol. 2010;28:15s Suppl; Abstr 10017.Google Scholar
- 26.George S, von Mehren M, Heinrich MC, Wang Q, Corless CL, Butrynski JE, et al. A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol. 29:2011 Suppl; Abstract 10007.Google Scholar